In Silico Mixed Ligand/Structure-Based Design of New CDK-1/PARP-1 Dual Inhibitors as Anti-Breast Cancer Agents

Area of Science:

• Oncology
• Molecular Biology
• Computational Chemistry

Background:

• Cyclin-Dependent Kinase 1 (CDK-1) and Poly(ADP-ribose) polymerase 1 (PARP-1) are key drivers in breast cancer progression.
• Targeting these proteins offers a potential synthetic lethality strategy for cancer therapy.

Purpose of the Study:

• To identify novel compounds with dual inhibitory activity against CDK-1 and PARP-1.
• To explore the potential of dual-target inhibitors as a monotherapy for breast cancer.

Main Methods:

• A virtual screening protocol combining ligand- and structure-based approaches was employed.
• The Biotarget Predictor Tool and hierarchical docking studies were utilized to screen the National Cancer Institute (NCI) database.
• Molecular Dynamics Simulation was used to confirm compound stability and binding interactions.

Main Results:

• Compound 645656 demonstrated significant affinity for both CDK-1 and PARP-1.
• The study validated a dual-target mechanism of action for compound 645656.
• Molecular Dynamics Simulations confirmed the stable complex formation of compound 645656 with both target proteins.

Conclusions:

• Compound 645656 is a promising dual inhibitor of CDK-1 and PARP-1.
• Dual-target inhibition represents a viable strategy for arresting breast cancer progression by simultaneously blocking cell cycle and DNA repair.
• Further investigation into compound 645656 as a potential breast cancer therapeutic is warranted.